Mark Stein, PhD, ABPP

Personal Statement

I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to  our behavioral group treatment programs and treatment recommendations.   The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves  diagnostic evaluations and consultations  for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for  individuals with ADHD.    I have  assisted in the development of several stimulant  and non stimulant medications, and participated in many clinical trials. Currently, we are   conducting a study  for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication  and  behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD,  and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.

Education

Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago

Department Affiliations

Other Affiliations

PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic

 

Center for Child Health, Behavior, and Development

 

Brotman Baty Institute

Recent Publications

Sequencing Stimulant Medication and Behavioral Parent Training in Multiplex ADHD Families: A Pilot SMART.
(2025 Feb 19)
J Clin Psychiatry 86(1):
Lui JHL, Chronis-Tuscano A, Almirall D, Whitlock KB, French W, Stein MA

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.
(2025 Feb 24)
Cancer Discov
Hugaboom MB, Wirth LV, Street K, Ruthen N, Jegede OA, Schindler NR, Shah V, Zaemes JP, El Ahmar N, Matar S, Savla V, Choueiri TK, Denize T, West DJ, McDermott DF, Plimack ER, Sosman JA, Haas NB, Stein MN, Alter R, Bilen MA, Hurwitz ME, Hammers H, Signoretti S, Atkins MB, Wu CJ, Braun DA

Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas.
(2025 Jan 23)
Clin Cancer Res
Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
(2024 Dec 30)
Nat Commun 15(1): 10743
Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont CF, Senesac JH, Bayle JH, Scripture CD, Chatwal MS, Bilen MA, Stadler WM, Becerra CR

Adjuvant therapy in renal cell carcinoma (RCC): progress, at last.
(2024 Nov 30)
Transl Cancer Res 13(11): 6448-6462
Bueno AN, Stein MN, Runcie K

Show complete publication list »
Edit Profile